75F40122F19006↗

Name: 75F40122F19006: Firm Fixed Price Award Center for Drug Evaluation (Cder) and Research Office of New Drugs - Office of Therapeutic Biologics and Biosimilars (Otbb) Biosimilar User Fee Act I Program - Biosimilar and Interchangeable Product Education, Uptake, and Imp
Creator: SpendQuery

FIRM FIXED PRICE AWARD CENTER FOR DRUG EVALUATION (CDER) AND RESEARCH OFFICE OF NEW DRUGS - OFFICE OF THERAPEUTIC BIOLOGICS AND BIOSIMILARS (OTBB) BIOSIMILAR USER FEE ACT I PROGRAM - BIOSIMILAR AND INTERCHANGEABLE PRODUCT EDUCATION, UPTAKE, AND IMP

Bpa Call · Food and Drug Administration · to Booz Allen Hamilton Inc (UEI JCBMLGPE6Z71) · data as of 2026-09-30

Obligated to date$500.0K4 actions

Current value$1.10Mwith options exercised

Period2022-08-10 → 2024-09-30current end date

What it is

Product or service: Support- Professional: Program Management/Support (PSC R408)
Industry: Administrative Management and General Management Consulting Services (NAICS 541611)
Contracting office: Fda Office of Acq Grant Svcs (75F401)
Competition: Full and open competition
Pricing: Firm fixed price
How it was bought: Blanket purchase agreement (BPA) · under 75F40122A00008
Where the work is: Montgomery, MD · district MD-08

Obligations by fiscal year

FY2023$500.0K

FY2024$0

SpendQuery holds FY2023 on; earlier years are on USAspending.gov.

Subcontractors: where the money went next

No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.

Every action

4 actions since 2022-11-30. Each is a modification or amendment with the money it added or took back.

Date	Modification	Kind	Amount	What the agency wrote
2024-08-26	P00004	Administrative change	$0	FIRM FIXED PRICE AWARD CENTER FOR DRUG EVALUATION (CDER) AND RESEARCH OFFICE OF NEW DRUGS - OFFICE OF THERAPEUTIC BIOLOGICS AND BIOSIMILARS (OTBB) BIOSIMILAR USER FEE ACT I PROGRAM - BIOSIMILAR AND INTERCHANGEABLE PRODUCT EDUCATION, UPTAKE, AND IMPL
2024-05-08	P00003	Administrative change	$0	FIRM FIXED PRICE AWARD CENTER FOR DRUG EVALUATION (CDER) AND RESEARCH OFFICE OF NEW DRUGS - OFFICE OF THERAPEUTIC BIOLOGICS AND BIOSIMILARS (OTBB) BIOSIMILAR USER FEE ACT I PROGRAM - BIOSIMILAR AND INTERCHANGEABLE PRODUCT EDUCATION, UPTAKE, AND IMPL
2023-07-31	P00002	Administrative change	$500.0K	FIRM FIXED PRICE AWARD CENTER FOR DRUG EVALUATION (CDER) AND RESEARCH OFFICE OF NEW DRUGS - OFFICE OF THERAPEUTIC BIOLOGICS AND BIOSIMILARS (OTBB) BIOSIMILAR USER FEE ACT I PROGRAM - BIOSIMILAR AND INTERCHANGEABLE PRODUCT EDUCATION, UPTAKE, AND IMPL
2022-11-30	P00001	Administrative change	$0	FIRM FIXED PRICE AWARD CENTER FOR DRUG EVALUATION (CDER) AND RESEARCH OFFICE OF NEW DRUGS - OFFICE OF THERAPEUTIC BIOLOGICS AND BIOSIMILARS (OTBB) BIOSIMILAR USER FEE ACT I PROGRAM - BIOSIMILAR AND INTERCHANGEABLE PRODUCT EDUCATION, UPTAKE, AND IMP

Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-09-30). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗